Loading...
•
Mar 31, 2021
Precigen Q1 2021 Earnings Report
Precigen's financial performance in Q1 2021 reflected progress in clinical programs and strategic scaling down of operations.
Key Takeaways
Precigen reported a net loss of $21.8 million, with a decrease in total revenues by $5.3 million compared to the prior year. The company highlighted progress in its clinical programs and the initiation of a Phase 1 study for PRGN-2012.
Advanced clinical programs, including UltraCAR-T trials and PRGN-2009, progressed as planned.
Initiated Phase 1 clinical trial of PRGN-2012 AdenoVerse immunotherapy.
Received orphan drug designation from the US FDA for PRGN-2012 in patients with recurrent respiratory papillomatosis (RRP).
Total revenues decreased by $5.3 million, primarily due to a decrease in collaboration and licensing revenues.
Forward Guidance
Precigen is on track to achieve its stated 2021 milestones.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...